Drug exposure The study cohort consisted of new users of GLP-1RAs (dulaglutide, exenatide, liraglutide, lixisenatide or semaglutide), SGLT2 inhibitors (canagliflozin, dapagliflozin or empagliflozin), metformin and other second- or third-line glucose-lowering drugs (thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sulfonylureas, meglitinides, -glucosidase inhibitors, insulin or a combination of glucose-lowering drugs)
Do not aim at the powder pellet
Their use is not prohibited by WADA, however some sporting authorities ban the use of hypoxic chambers during competitions under their sport rules
A new study suggests that semaglutide, the active ingredient in GLP-1 drugs like Ozempic and Wegovy could help treat alcohol use disorder